Treatment of the Nephrotic Syndrome with Etanercept in Patients with the Tumor Necrosis Factor Receptor-Associated Periodic Syndrome

doi:10.1056/NEJM200010053431412

Volume 343:1044-1045		October 5, 2000		Number 14

Treatment of the Nephrotic Syndrome with Etanercept in Patients with the Tumor Necrosis Factor Receptor–Associated Periodic Syndrome

Since this article has no abstract, we have provided an extract of the first 100 words of the full text and any section headings.

Full Text

Purchase this article

Add to Personal Archive

Add to Citation Manager

Notify a Friend

E-mail When Cited

PubMed Citation

To the Editor: The tumor necrosis factor (TNF) receptor–associatedperiodic syndrome is a dominantly inherited, chronic inflammatorycondition characterized by lifelong febrile attacks of abdominaland musculoskeletal pain associated with skin lesions. The attacksvary in severity and in frequency, usually last from 3 to 21days, and respond to high-dose corticosteroids. Soluble TNFreceptors can inhibit TNF activity by binding and preventingthe interaction of TNF- ${alpha}$ (TNFSF2) with its cell-surface receptor.Recombinant human TNF receptor (TNFRSF1B) (p75):Fc fusion protein(etanercept) inhibits the activity of TNF in vitro and reducesinflammation in animal models.¹

We evaluated a woman with the . . . [Full Text of this Article]

References

This article has been cited by other articles:

Lionaki, S., Siamopoulos, K., Theodorou, I., Papadimitraki, E., Bertsias, G., Boumpas, D., Boletis, J. (2009). Inhibition of tumour necrosis factor alpha in idiopathic membranous nephropathy: a pilot study. Nephrol Dial Transplant 24: 2144-2150 [Abstract] [Full Text]
Furst, D E, Keystone, E C, Kirkham, B, Fleischmann, R, Mease, P, Breedveld, F C, Smolen, J S, Kalden, J R, Burmester, G R, Braun, J, Emery, P, Winthrop, K, Bresnihan, B, De Benedetti, F, Dorner, T, Gibofsky, A, Schiff, M H, Sieper, J, Singer, N, Van Riel, P L C M, Weinblatt, M E, Weisman, M H (2008). Updated consensus statement on biological agents for the treatment of rheumatic diseases, 2008. Ann Rheum Dis 67: iii2-iii25 [Full Text]
Furst, D E, Breedveld, F C, Kalden, J R, Smolen, J S, Burmester, G R, Sieper, J, Emery, P, Keystone, E C, Schiff, M H, Mease, P, van Riel, P L C M, Fleischmann, R, Weisman, M H, Weinblatt, M E (2007). Updated consensus statement on biological agents for the treatment of rheumatic diseases, 2007. Ann Rheum Dis 66: iii2-iii22 [Full Text]
Fernandez-Nebro, A, Urena, I, Irigoyen, M V, Garcia-Vicuna, R, Konno, S, Iizuka, M, Horie, Y, Itou, H, Shindo, K, Watanabe, S (2006). Anti-TNF-{alpha} for treatment of amyloidosis associated with Crohn's disease * Author's reply.. Gut 55: 1666-1667 [Full Text]
Touitou, I, Perez, C, Dumont, B, Federici, L, Jorgensen, C (2006). Refractory auto-inflammatory syndrome associated with digenic transmission of low-penetrance tumour necrosis factor receptor-associated periodic syndrome and cryopyrin-associated periodic syndrome mutations.. Ann Rheum Dis 65: 1530-1531 [Full Text]
Yuksel, S., Yalcinkaya, F., Acar, B., Ozcakar, Z. B., Ozturk, B., Ekim, M. (2006). Clinical improvement with infliximab in a child with amyloidosis secondary to familial Mediterranean fever. Rheumatology (Oxford) 45: 1307-1308 [Full Text]
Kallinich, T, Haffner, D, Rudolph, B, Schindler, R, Canaan-Kuhl, S, Keitzer, R, Burmester, G R, Roesen-Wolff, A, Roesler, J (2006). "Periodic fever" without fever: two cases of non-febrile TRAPS with mutations in the TNFRSF1A gene presenting with episodes of inflammation or monosymptomatic amyloidosis. Ann Rheum Dis 65: 958-960 [Abstract] [Full Text]
Lamprecht, P, Moosig, F, Adam-Klages, S, Mrowietz, U, Csernok, E, Kirrstetter, M, Ahmadi-Simab, K, Schroder, J O, Gross, W L (2004). Small vessel vasculitis and relapsing panniculitis in tumour necrosis factor receptor associated periodic syndrome (TRAPS). Ann Rheum Dis 63: 1518-1520 [Abstract] [Full Text]
Drewe, E., Huggins, M. L., Morgan, A. G., Cassidy, M. J. D., Powell, R. J. (2004). Treatment of renal amyloidosis with etanercept in tumour necrosis factor receptor-associated periodic syndrome. Rheumatology (Oxford) 43: 1405-1408 [Abstract] [Full Text]
Ravindran, J., Shenker, N., Bhalla, A. K., Lachmann, H., Hawkins, P. (2004). Case report: response in proteinuria due to AA amyloidosis but not Felty's syndrome in a patient with rheumatoid arthritis treated with TNF-{alpha} blockade. Rheumatology (Oxford) 43: 669-672 [Full Text]
Grateau, G. (2004). Clinical and genetic aspects of the hereditary periodic fever syndromes. Rheumatology (Oxford) 43: 410-415 [Abstract] [Full Text]
Merlini, G., Bellotti, V. (2003). Molecular Mechanisms of Amyloidosis. NEJM 349: 583-596 [Full Text]
Verschueren, P, Lensen, F, Lerut, E, Claes, K, De Vos, R, Van Damme, B, Westhovens, R (2003). Benefit of anti-TNF{alpha} treatment for nephrotic syndrome in a patient with juvenile inflammatory bowel disease associated spondyloarthropathy complicated with amyloidosis and glomerulonephritis. Ann Rheum Dis 62: 368-369 [Full Text]
Drewe, E., McDermott, E. M., Powell, P. T., Isaacs, J. D., Powell, R. J. (2003). Prospective study of anti-tumour necrosis factor receptor superfamily 1B fusion protein, and case study of anti-tumour necrosis factor receptor superfamily 1A fusion protein, in tumour necrosis factor receptor associated periodic syndrome (TRAPS): clinical and laboratory findings in a series of seven patients. Rheumatology (Oxford) 42: 235-239 [Abstract] [Full Text]
Drenth, J. P. H., van der Meer, J. W. M. (2001). Hereditary Periodic Fever. NEJM 345: 1748-1757 [Full Text]

Comments and questions? Please contact us.